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Abstract 28 
Introduction:  During pregnancy, fetal stem cells can transfer to the maternal circulation and participate in tissue 29 
repair. How they transmigrate across maternal endothelial barriers and whether they can subsequently influence 30 
maternal endothelial integrity is not known.   31 
Methods:  Mesenchymal stem cells (WJ-MSC) were isolated from Wharton’s jelly and their interactions with human 32 
uterine microvascular endothelial cell (HUtMEC) monolayers, junctional occupancy and expression 33 
/phosphorylation of vascular endothelial (VE)- cadherin and vascular endothelial growth factor (VEGF-A) secretion 34 
was studied over 48h by real time, confocal microscopy, immunoblotting and ELISA.   35 
Results: WJ-MSC displayed exploratory behaviour with interrogation of paracellular openings and spreading into 36 
the resultant increased gaps followed by closing of the endothelium over the WJ-MSC. 62% of added cells crossed 37 
within 22h to sub-endothelial niches . There was a concomitant loss of junctional VE-cadherin in HUtMEC followed 38 
by a full return and increased VE-cadherin expression after 22h. During early hours, VE-cadherin showed a transient 39 
phosphorylation at Tyrosine (Tyr)-685 when VEGF-A secretion were high. From 16 to 22h, there was increased de-40 
phosphorylation of Tyr-731. Anti-VEGF-A blocked Tyr-685 phosphorylation but not the decrease in P-Tyr731; this 41 
partially inhibited WJ-MSC transmigration.   42 
Discussion:  Fetal WJ-MSC can traverse uterine endothelial monolayers by mediating a non-destructive paracellular 43 
pathway. They can promote junctional stability of uterine endothelium from the sub-endothelial niche. 44 
Mechanistically, WJ-MSC induces VEGF-dependent phosphorylation events linked with paracellular permeability 45 
and VEGF-independent de-phosphorylation events associated with leukocyte extravasation. Our data also allows 46 
consideration of a possible role of fetal MSC in mature functioning of the uterine vasculature needed for optimal 47 
utero-placental perfusion.  48 
 49 
Key words: Human umbilical mesenchymal stem cells, Human uterine microvascular endothelial cells, 50 
Transendothelial migration, VE-cadherin, P-Tyr685, P-Tyr731. 51 
 52 
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Introduction 56 
The presence of pregnancy-associated fetal progenitor cells in the maternal circulation is well documented. They can 57 
be detected in the mother’s peripheral blood from the first trimester of pregnancy, with numbers increasing as 58 
pregnancy progresses; indeed persistent microchimeric fetal cells can remain in the maternal circulation decades 59 
after birth [1-3]. The maternal blood in placental intervillous spaces has been shown to contain fetal cells even at 60 
term, strengthening the observation that these cells continue to cross the placental barrier throughout gestation [4]. 61 
Cells from all three embryonic germ layers; ectoderm, endoderm and mesoderm have been identified in maternal 62 
peripheral blood and damaged maternal tissues such as brain, kidney and heart [5-9]. They are thought to play an 63 
active role in the repair of maternal tissues; caudal related homeobox 2 (CDX2) cells of fetal/placental origin have 64 
been shown to home into injured myocardial endothelium in mice and undergo differentiation into diverse cardiac 65 
lineages [10]. The re-modelling of uterine spiral arteries up to one-third of the myometrium by placenta derived 66 
extra-villous trophoblast cells (EVT) in order to ensure high flow, low resistance conduits of maternal blood flow to 67 
the placenta is well documented [11]. EVT are thought to replace the smooth muscle layer of the arteries, with 68 
subsequent re-endothelisation or trans-differentiation to endothelial cells. Whether fetal mesenchymal stem cells 69 
could play a part in this has not been addressed.  Other cell types, specifically fetal endothelial colony forming cells 70 
isolated from human cord blood and injected into the fetal heart have been shown to transmigrate from the fetus to 71 
the uterus and home into and aid expansion of mouse uterine vessels in pregnancy [12]. These authors also located 72 
endothelial-associated fetal cells in the human myometrial microvessels at term and hypothesise that fetal stem cells 73 
play a role in influencing the necessary expansion of maternal vascular supply to the placenta.  How fetal cells, 74 
whether endothelial colony- forming or mesenchymal stem cells, cross the maternal endothelial barrier, incorporate 75 
into the uterine vasculature and their influence, if any, on the endothelium requires investigation. 76 
 Mesenchymal stem cells (MSC) can be found in perivascular niches of the placenta and umbilical cord [13, 14]. 77 
They are of  interest in regenerative medicine, given their potential to promote tissue regeneration [15] and enhance 78 
vascular barrier integrity [13, 16].  WJ-MSC can promote neovascularisation, re-endothelialisation and junctional 79 
integrity [13, 17]. In a previous study we have shown that WJ-MSC can cross the fetal human umbilical vein 80 
endothelial monolayers using a paracellular route, with full repair of vascular endothelial cadherin (VE-cadherin) 81 
junctions once a sub-endothelial niche has been reached [13]. Whether a similar non-destructive mechanism is 82 
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employed by these fetal stem cells to cross the maternal endothelium, including the uterine myometrial 83 
microvascular endothelium require elucidation.  84 
The endothelial paracellular pathway, and the adhesion molecules present therein respond to physiological and 85 
pathological factors including inflammatory mediators and permeability increasing agents such as VEGF and 86 
histamine [18-20]. Activation of Src family kinases and tyrosine phosphorylation of VE-cadherin has been 87 
associated with a loss of barrier function. VEGF has been shown to increase phosphorylation of Tyr-685 in human 88 
umbilical vein cells [19, 21]. However controversy exists in the literature, with Adam et al. [22] showing that Src-89 
induced tyrosine phosphorylation of VE-cadherin is not sufficient to promote an increase in monolayer permeability 90 
in human dermal microvascular cells.  A recent in vivo study suggests that the opening of endothelial junctions for 91 
the passage of plasma proteins or leukocytes depends on two different tyrosine residues of VE-cadherin where 92 
phosphorylation is regulated in opposite ways. Using knock-in mice expressing a Y685 mutant of VE-cadherin or a 93 
Y731F mutant, the authors demonstrated phosphorylation and dephosphorylation of VE-cadherin at Tyr685 and 94 
Tyr731 governs induction of vascular permeability or leukocyte diapedesis [23]. The latter required internalisation 95 
of VE-cadherin via tyrosine phosphatase SHP-2 with the resultant frank opening necessary for leukocyte 96 
paracellular trafficking. Which pathway, or both is utilised by WJ-MSC needs addressing.  MSc derived from bone 97 
marrow have been shown to cross primary human lung and heart microvascular endothelial monolayers [24] in a 98 
fashion similar to leukocytes,  although the duration of the process: from encounter to sub-endothelial destination, 99 
took longer than that for leukocytes crossing at sites of inflammation [13, 19, 24, 25].   100 
Using real time, confocal microscopy, ELISA and protein expression analyses this study specifically investigated 101 
the spatio-temporal events when fetal WJ-MSC encounter confluent maternal endothelial cell monolayers, the 102 
chosen transendothelial migration pathway and the VE-cadherin dynamics and phosphorylation events which would 103 
allow physiological paracellular extravasation. The ability of these cells to influence maternal endothelial junctional 104 
maturity from sub-endothelial niches was also investigated. The use of primary uterine microvascular cells allowed 105 
insights to fetal and maternal interactions per se as well as a possible role of fetal mesenchymal stem cells in mature 106 
functioning of the uterine vasculature needed for optimal utero-placental perfusion.  107 
 108 
 109 
 110 
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Materials and Methods 111 
Tissue Collection and Ethical Approval 112 
Term umbilical cords (n=8) were obtained at elective Caesarean section from normal pregnancies with informed 113 
patient consent and full ethical approval (REC Ref 14/SC/ 1194; NHS Heath Research Authority, UK). The work 114 
described here has been carried out in accordance with The Code of Ethics of the World Medical Association 115 
(Declaration of Helsinki). 116 
5 separate isolates of primary human uterine myometrial microvascular endothelial cells (C-12295; Passage 2) were 117 
bought from PromoCell, Heidelberg, Germany. 118 
Antibodies used (concentration, clone and company): CD45 – FITC (0.25 µg/ml, Clone IM2078U, 119 
Beckman Coulter); CD34 – FITC (0.25 µg/ml, A86354, Beckman Coulter); CD44 – PE (0.25 µg/ml, IM0845, 120 
Beckman Coulter); CD29 – FITC (0.25 µg/ml PN IM0791U, Beckman Coulter); CD105 – FITC (0.25 µg/ml, 121 
323203,ebioscience); CD73 – APC ( 0.125 µg/ml, 17-0739, ebioscience); CD90 – PE (0.25 µg/ml, 12-0909, 122 
ebioscience); CDHLA-DR – FITC (0.25 µg/ml, 307603,ebioscience); CD19 – APC (0.25 µg/ml, 12-0199, 123 
ebioscience); CD14 – PE (0.25 µg/ml,  17-0149, ebioscience); VE-cadherin (CD144; 5 µg/ml; 2500,Cell 124 
Signalling, UK);  VE-cadherin (6 µg/ml, 55-7H1, Pharmingen, BD Biosciences); Vwf (5 µg/ml, IS527,Dako); 125 
CD31(5 µg/ml, BBA7, R&D Systems); Cytokeratin 7(12.4 µg/ml; M7018,Dako); VE-cadherin p-Tyr 685 (2 126 
µg/ml, CP1981, ECM Biosciences); VE-cadherin p-Tyr731 (2 µg/ml, Ab27776, abcam); β-Actin (0.4 µg/ml, 127 
A5316, Sigma-Aldrich); VEGF-A (2 µg/ml, MAB293, R&D Systems); IgG secondary antibodies for IB (1:4000, 128 
Li-Cor Bioscience).   129 
Isolation and characterization of cells 130 
WJ-MSC were non-enzymatically isolated from umbilical cord segments and cultured up to Passage 4 in stem cell 131 
growth medium (DMEM/Low Glucose) with 0.1% antibiotic/antimycotic solution and 15 % Fetal Bovine Serum 132 
using the methods previously described [13]. They were characterised to be mesenchymal stem cells by flow 133 
cytometry, being positive for mesenchymal CD29, CD105, CD90, CD73, CD44 and negative for the haematopoetic 134 
markers CD34, CDHLA-DR, CD14, CD19 & CD45. The ability of these cells to differentiate into osteocytes, 135 
chondrocytes and adipocytes if induced was also tested separately [13].  Undifferentiated WJ-MSC were labelled 136 
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with the red fluorescent dye PKH26 (15 µM; Sigma-Aldrich, UK) as per manufacture’s instruction prior to co-137 
culture studies.  138 
HUtMEC on 1 % gelatin-coated coverslips were grown to confluence in endothelial growth medium (MV) from 139 
PromoCell which contained 5.56 mM glucose,  FCS, ECGS, heparin, hydrocortisone but no extra VEGF;  pH 140 
7.4.  100 IU/mL penicillin, 100 µg/mL streptomycin, 0.25 µg/mL Amphotercin B was added to MV before use.   141 
HUtMEC and WJ-MSC monolayers and co-cultures (see below) were further characterized by 142 
immunocytochemistry with antibodies against the endothelial markers VE-cadherin and CD31; mesenchymal 143 
marker CD29-FITC, anti-VEGF-A and mAb against cytokeratin 7 (Dako, UK). Rabbit-anti human VE-cadherin was 144 
used for double labelling.  HUVEC monolayers at passage 2 were used as a positive endothelial control.  Briefly, 145 
cells were fixed with 1% paraformaldehyde, permeabilized (0.15% Triton X-100; 10 min), blocked in 5% goat 146 
serum and incubated overnight (4 ˚C) with the primary antibodies.   Appropriate TRITC or FITC conjugated 147 
secondary antibodies (Sigma) were then used. Coverslips were mounted using Vectorshield (Vector Lab Inc, USA). 148 
Propidium iodide (PI; 1.5µg/ml) or 4’6-diamidino-2-phenyl indole (DAPI; 1µg/ml) was used to counterstain nuclei. 149 
Images were acquired with Nikon fluorescence microscope and NIS elements F3.0. 150 
Co-culture studies of WJ-MSC with HUtMEC   151 
Similar to our previous study design using HUVEC [13], once HUtMEC reached 70 ٪ confluence, media was 152 
changed to a 50:50 mixed media (endothelial: stem cell media). On full confluence (18 -24h later) isolated PKH26 153 
labelled WJ-MSC were seeded on top of the confluent monolayer (1: 5 ratio) per coverslip [13, 16]. HUtMEC 154 
monolayers without added WJ-MSC acted as controls.  All experiments were repeated 4 times.  155 
Real Time Observations 156 
Co-cultures of WJ-MSC with HUtMEC on gelatinized glass-bottomed tissue culture dishes (Ibidi GmBH, Germany) 157 
were observed for 24 hours with a wide-field fluorescence imaging system (Deltavision Elite; Applied Precision, 158 
USA). Z- stack images at 2 different focal planes were acquired every 15 min. Data analysis was carried out using 159 
Volocity software (Perkin Elmer, UK).  160 
Quantitative analysis of endothelial junctional integrity and migrating WJ-MSC  161 
Based on preliminary observations of co-cultures from 0- 48h, and known behaviour of WJ-MSC on HUVEC 162 
monolayers [13], confluent monolayers of HUtMEC with/without added PKH26-labelled WJ-MSC at 0, 30, 60, 90 163 
min, 2, 16, 22 and 48 h were immunolabelled for VE-cadherin as stated above for analyses of early and late 164 
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interactions.  Systematic random sampling was used to acquire 10 images per coverslip for each chosen duration and 165 
repeats. After blinding, the % of paracellular clefts per image was categorised according to VE-cadherin staining 166 
pattern: continuous or discontinuous (including total loss from cell-cell cleft).  To ensure an equal chance of being 167 
counted, a grid was used and clefts from every other square which did not cross the “forbidden line” [27, 28] were 168 
counted. Data were analysed using Two-way ANOVA (Prism 6) and Sidak’s multiple comparison test. Statistical 169 
significance was taken at p<0.05.  170 
Using Z-focus steps, the location of WJ-MSC in respect to HUtMEC monolayer, whether above (apical) or below 171 
(sub-endothelial) and their proximity to discontinuous junctions were recorded at 30, 60, 90 min and 2, 16 and 22h.  172 
Confocal imaging 173 
2 and 22h immunostained coverslips were further analysed with confocal scanning microscopy (Zeiss Axiovision; 174 
Zeiss, Germany).  Optical slices (0.5 - 0.6 µm intervals) were taken and composite images were tilted at the Z-axis 175 
with Volocity software to visualise transmigration pathways and the apical/basal location of stem cells for the 176 
chosen durations. 177 
 Immunoblot analysis 178 
Confluent HUtMEC monolayers were co-cultured with/without unlabelled WJ-MSC on 6 well plates as above. 179 
Based on the observed VE-cadherin dynamics, the early hours of interaction (0, 30, 60 and 120 min) and late (22 180 
and 48h) were chosen to measure VE-cadherin expression and its’ phosphorylation status at Tyr-685 or Tyr-731. A 181 
third study group included co-cultures interacted in the presence of anti-human VEGF-A (2µg/ml) for 2 and 22h.  182 
Briefly, cells were scraped and lysed in 200 µl Lysis buffer (50 mM Tris-HCL pH 7.4;  + 10 % [vol/vol] glycerol + 183 
280 mM NaCl + 0.1% Triton X 100 + 50 mM NaF + 2 mM EGTA + 0.2 mM EDTA + 1 mM NA3VO4 +  0.1 mM 184 
phenylmethylsulfonyl fluoride [PMSF] + 1 mM Dithiothreitol (DTT) and Complete [Roche] protease inhibitors) for 185 
10 min on ice.  De-natured proteins were separated in a 4-20% gradient polyacrylamide gel (Bio-Rad, UK) after 186 
equal loading [13]. They were incubated with antibodies consecutively with immunoglobulins removed as described 187 
by Begitt et al [29].  Optical densities were measured and analysed using the Li-cor Odyssey system and Image-J. 188 
Normalised values, against β-actin and VE-cadherin were compared by One-way ANOVA and unpaired student’s t-189 
test [13]. Experiments were repeated three times using three different isolates. 190 
ELISA Assay 191 
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VEGF-A (165 and 121) concentrations in the condition media from co-cultures of WJ-MSC and HUtMEC at 2, 22, 192 
48h were measured using a commercially available kit (R&D Systems, USA).  Conditioned media from co-cultures 193 
grown in the presence of neutralising anti-VEGF-A antibody were measured as was conditioned media from WJ-194 
MSC or HUTMEC monolayers only.  The optical absorbance was read at 450 nm (TECAN, Switzerland). VEGF-A 195 
concentrations were calculated from standard curves and analysed with One-way ANOVA.  Internal repeats (x3) 196 
from two different isolates were compared.  197 
 198 
Results 199 
VE-cadherin junctional dynamics in co-cultures.  200 
HUtMEC showed immunopositivity to the endothelial markers VE-cadherin and CD31 (Fig.1 A,B) with strong 201 
continuous staining at cell-cell contact regions of confluent monolayers. Counts of junctions in mixed media at 202 
different durations revealed a slight decrease in continuity after 30 min exposure to mixed media but this was not 203 
found to be statistically significant when compared to controls in full media. Values from subsequent 2h, 16h and 204 
22h in mixed media were not statistically different from each other, 30 min duration or control (One way ANOVA 205 
with Tukeys Multiple Comparison test; Fig.1 C-G).   206 
On addition of labelled WJ-MSC to confluent HUtMEC layers, WJ-MSC began to alter their shape, from rounded to 207 
more flattened cuboidal to elongated spindle shape with time. 30 min after initial interaction, 10% of cells displayed 208 
changed morphology (Fig 2 A); by 2h, <40% of cells remained rounded and could be found in apical positions only.  209 
(Fig 2 B). A contact-mediated change of VE-cadherin staining pattern in HUtMEC, from continuous to 210 
discontinuous or total loss, was observed from 30 min onwards (Fig.2 C, D). This reached statistical significance (P 211 
< 0.0001) at 2h with 63 + 4.6% of clefts showing continuous staining compared to controls (83.5 + 3.5 %).  212 
Disrupted clefts and frank openings at tri-cellular junctions in the monolayer were associated with overlying or 213 
transmigrating WJ-MSC (Fig. 2 C-E). At 16h co-culture there was evidence of recovery in regions devoid of 214 
apically resident stem cells; 79 + 1.7 % of junctions now displayed continuous VE-cadherin.  At 22h, WJ-MSC were 215 
found mostly in sub-endothelial position, underlying fully confluent endothelial monolayers with continuous VE-216 
cadherin staining (Fig. 2 F). This was confirmed by the Z tilts acquired at 2 and 22h (Fig.2 G, H). At 22h, 94 + 2.7 217 
% of clefts showed continuous VE-cadherin staining compared to 82.2 + 2.5 % in duration matched controls (p < 218 
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0.001) suggestive of increased junctional occupancy of VE-cadherin in the stem cell treated HUtMEC (Fig.2 I).  219 
WJ-MSC demonstrated negative immunoreactivity to VE-cadherin throughout.  220 
 Counts of PKH26 labelled WJ-MSC at apical, transmigrating or sub-endothelial locations confirmed that 221 
transmigration started from 30 minutes (5% of total cells in field of view) with the number of extravasating cells 222 
increasing with time (Fig. 2 J). The rate of migration was highest in the early hours, with 48 + 15 % of cells found in 223 
sub-endothelial locations at 2h. Migration continued for a further twelve hours with 98 + 2% of WJ-MSC counted at 224 
sub-endothelial positions at 22h.  Not all cells crossed the endothelial barrier, of the initial 20,000 cells placed on 225 
confluent HUtMEC per coverslip, only 62 + 18% of cells crossed within 22h.  226 
Real time visualisation of WJ-MSC/ HUtMEC interactions  227 
Real time microscopy confirmed that interaction with WJ-MSC did not result in any observed apoptosis or 228 
detachment of the uterine endothelial cells. HUtMEC remained as a flattened monolayer throughout the 48h 229 
observation period (Fig.3).  Upon addition, the PKH26-labelled WJ-MSC displayed a prolonged exploratory 230 
behaviour, with classical membrane blebbing and amoeboid movement (Fig. 3 A-M) over the uterine endothelial 231 
monolayer. After the lag phase, WJ-MSC was observed to change shape towards the spindle-shaped morphology 232 
(Fig.3 N-P), interrogate endothelial paracellular clefts and populate the increased paracellular gaps in HUtMEC 233 
monolayers (Fig.3 N-R).   234 
Analyses of VE-cadherin expression/ phosphorylation status   235 
The expression and phosphorylation status of VE-cadherin was altered depending on presence and duration of stem 236 
cell interaction (Fig.4 A-E).  In the early hours of co-culture, 0, 30, 60 and 120 min there were no change in the total 237 
expression of VE-cadherin. At the post-migration times of 22 and 48h co-culture, there was a statistically significant 238 
(p< 0.01) increase in VE-cadherin expression, compared to control or early hours (Fig. 4A, D).  239 
HUtMEC treated with WJ-MSC showed a significant increase in p-Tyr685 at early hours (30, 60 and 120 min) 240 
reaching maximal value at 2h (p<0.001), followed by a decrease at 22h and return to control values at 48h (Fig.4 A, 241 
B).  Tyr731 showed basal level of phosphorylation similar to the controls at the early hours of interaction (Fig.4 C). 242 
This was followed by a dramatic decrease in p-Tyr731 expression at 2 and 22h (p<0.01).  By 48h, both 243 
phosphorylation and de- phosphorylation status of VE-cadherin returned to normal.  244 
Addition of anti-VEGF neutralising antibodies to co-cultures blocked the phosphorylation of Tyr685 at 2 and 22h, 245 
with a significant decrease at 2h (p<0.01; Fig 4E). The later Tyr731 de- phosphorylation was not affected.  246 
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Neutralisation of VEGF resulted in reduced migration of WJ-MSC with 25% fewer cells found in sub-endothelial 247 
locations at 2h.  Cells continued to cross the endothelial monolayer in the period dominated by the unaltered Tyr731 248 
de-phosphorylation. At 22h, only 47 + 6 % of cells, compared to 90 + 8% in non-neutralised controls, were found 249 
underlying the HUtMEC monolayer (Fig. 4 F).   250 
Secretion of VEGF during early hours of interaction 251 
The conditioned media (CM) from WJ-MSC or HUtMEC monolayers showed negligible concentrations of VEGF-A 252 
(165,121) present (Fig.5 A). In cultures of HUtMEC challenged with mixed media there was a detectable level of 253 
VEGF-A levels in the supernatant measured at 2h but not at 22h. When HUtMEC was co-cultured with WJ-MSC 254 
there was a statistically significant increase in VEGF-A levels in the supernatant at 2h (p<0.001) followed by a 255 
decrease at 22h (p<0.05). No VEGF-A was detected by 48h.  Supernatants of co-cultures grown in the presence of 256 
VEGF-A neutralising antibodies did not contain measurable VEGF-A at 2 or 22h. Immunocytochemistry revealed 257 
VEGF-A presence in HUtMEC and WJ-MSC (Fig.5 B-D). WJ-MSC appeared to have higher intensity of staining at 258 
2h co-culture (Fig 5B).  259 
Cytokeratin-7 expression in endothelial and mesenchymal stem cells 260 
In monocultures, 29 + 4% of  HUtMEC were immunopositive to CK7 whilst still expressing endothelial markers 261 
(Fig.6 A,B);  HUVEC were found to contain a higher percentage (81+ 6%) of CK-7 expressing cells (Fig.6 C,D) 262 
whilst 30 + 3% of the WJ-MSC were positive to CK7 (Fig.6 E) whilst also expressing mesenchymal markers (Fig.6 263 
F).  In HUtMEC-WJMSC co-cultures, no increase was seen in the percentage of CK7+ cells in either cell type (Fig.6 264 
G, H). CK7+ WJ-MSC was found in both apical and sub-endothelial positions of HUtMEC monolayers at 2 or 22h 265 
of co-culture.   266 
Discussion 267 
This in vitro study is the first to show that fetal mesenchymal stem cells derived from the Wharton’s jelly of term 268 
human umbilical cords can cross monolayers of microvascular endothelial cells derived from the human 269 
myometrium in a non-destructive manner without detaching the endothelial cells of the monolayer. Moreover, these 270 
fetal mesenchymal cells demonstrated a paracellular egress to sub-endothelial niches with disruption of VE-cadherin 271 
junctions followed by repair and increased up-regulation of VE-cadherin.  In the early hours of co-culture, WJ-MSC 272 
induced phosphorylation of the Tyr 685 residue of VE-cadherin which has been implicated in initiation of vascular 273 
permeability. This was followed by de-phosphorylation of Tyr731, implicated in regulation of leukocyte 274 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
11 
 
  
extravasation.  The early VE-cadherin discontinuity at cell-cell junctions and phosphorylation at Tyr685 may be 275 
induced by soluble factors secreted during co-culture. Elevated levels of VEGF were found in the supernatant prior 276 
to and during maximal rate of transendothelial migration of WJ-MSC.  Both cell types were capable of secreting 277 
VEGF with WJ-MSC showing higher intensity of staining at 2h co-culture.  278 
HUtMEC have been used previously to investigate trophoblast invasion and integration into the endothelial layers 279 
[30]. Trophoblast cells were shown to actively displace endothelial cells and form trophoblast islands in the same 280 
plane as the endothelial cells. WJ-MSC appeared not to displace HUtMEC but rather transmigrated singly to sub-281 
endothelial regions. This behaviour was similar to that when WJ-MSC encountered fetal endothelial cells isolated 282 
from umbilical cords (13). Sipos et al. [12] demonstrated that human fetal endothelial colony forming cells can cross 283 
the placental feto-maternal barrier and transmigrate to the maternal uterine vasculature in mice. These cells 284 
exhibited mesenchymal markers (CD105 & CD 146) and endothelial markers (CD 31) and VEGFR-2, but not 285 
hematopoietic markers. In our study we demonstrate that fetal mesenchymal stem cells, isolated from cords obtained 286 
from elective Caesarean sections, can also traverse maternal endothelial cells and influence their junctional integrity 287 
once sub-endothelial locations are reached.   288 
WJ-MSC displayed non-apoptotic blebbing, amoeboid movement and interrogation of intercellular openings (Fig. 3) 289 
as early events in their exploration of the uterine endothelial monolayer. This is reminiscent of bone marrow 290 
mesenchymal cell interactions with TNF- alpha stimulated endothelial cells [24]. There was a minimum time lag of 291 
around 30 min before WJ-MSC transmigration was observed with a higher rate of migration between 30 min to 2h.  292 
The differential rate of migration over the study period suggests to the presence of two populations: fast and slow 293 
transmigrators. Furthermore, only 60% of cells placed on the endothelial monolayers crossed suggesting that in our 294 
non-stimulated confluent monolayers, the microenvironment may have favoured cells capable of peri-295 
vascular/pericytic commitment.   The observed prolonged exploration shown by WJ-MSC and the induced 296 
paracellular gaps in HUtMEC monolayer suggests a paracrine conversation between WJ-MSC and the endothelial 297 
cells. Indeed, VEGF levels increased in co-culture supernatants at 30 min, with highest levels measured at 2h. MSC 298 
isolated from chorionic blood vessels of the placenta has been shown to secrete VEGF and induce increased 299 
angiogenesis in endothelial cells from chorionic arteries [31]. It is therefore not surprising that WJ-MSC, of same 300 
mesodermal origin also shows a similar secretory capability when challenged with HUtMEC. The highest 301 
percentage of junctional disruption, defined by loss or discontinuous VE-cadherin localisation was also recorded at 302 
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2h.  The ability of VEGF to disrupt VE-cadherin junctions is well established [18, 20, 28]. Junctional VE-cadherin 303 
profiles returned to normal when a majority of WJ-MSC were resident underneath the endothelial monolayers. 304 
Indeed, at 22h there was increased monolayer integrity manifested by a significantly higher percentage of 305 
paracellular clefts showing continuous VE-cadherin labelling compared to HUtMEC monolayers without stem cells. 306 
The higher VE-cadherin protein expression at 22 and 48h also indicates an induced increase in junctional maturity. 307 
WJ-MSC were seen to expel exosomes (data not shown); the role of these in the subsequent upregulation of VE-308 
cadherin is under investigation in our lab. Although our data is from in vitro studies, the observed non-destructive 309 
migration and post-migratory influence on junctional integrity of uterine endothelial cells is encouraging and offers 310 
possible mechanisms as to how fetal stem cells can traffic and reside in maternal tissue. Certainly, the data 311 
strengthens the promise of the usefulness of WJ-MSC in vascular repair of maternal/adult vasculature. 312 
The molecular mechanism utilised by the fetal stem cells to cross the uterine endothelial barrier, appeared to involve 313 
transient phosphorylation of VE-cadherin at Tyr685. The resultant transmembrane redistribution of VE-cadherin 314 
from junctional regions may have allowed early egress of the spindle-shaped WJ-MSC. This was partially blocked 315 
by VEGF-A neutralising antibodies, which also inhibited phosphorylation of VE-cadherin. VEGF-A have been 316 
shown to target the Y685 residue of VE-cadherin [21]. Increased P-Y685 in our study coincided with increased 317 
VEGF-A measured at the early hours of co-culture.  VEGF-A was immunolocalised to both HUtMEC and WJ-318 
MSC, the latter showed higher intensity of staining at 2h.  Of course, VEGF-A may only be one contributory 319 
secretory factor, given WJ-MSC can secrete a repertoire of permeability enhancing factors and cytokines which are 320 
also able to induce SRC-mediated VE-cadherin changes. Although we did not observe intracellular migration of the 321 
fetal stem cells, we cannot exclude this and it may also have contributed to why we only saw a partial inhibition of 322 
transmigration with neutralising antibodies against VEGF-A (25% reduction).  As stated before, Wessel et al [19] 323 
showed that whilst Tyr685 phosphorylation induces vascular solute permeability, de-phosphorylation of VE-324 
cadherin at Tyr731 selectively regulates leukocyte extravasation. In their study, siRNA blocking of the de-325 
phosphorylation impaired VE-cadherin internalisation and reduced leukocyte migration by 36 %.  In the WJ-326 
MSC/HUtMEC co-cultures, the Y685 phosphorylation was followed by enhanced de- phosphorylation of Try731 at 327 
2h; this coincided with highest recorded loss of junctional VE-cadherin and frank inter-cellular gaps. Addition of 328 
anti-VEGF antibody did not affect this de- phosphorylation suggesting VEGF independence.  Overall our data 329 
suggests that a proportion of WJ-MSC may utilise pathways created by early VEGF-dependent VE-cadherin 330 
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perturbations at transmembrane domains, whilst the remainder may use the later VEGF-independent Tyr 731 de-331 
phosphorylation events that lead to internalisation of VE-cadherin and increased disruption of junctions. The two 332 
putative mechanisms are also suggestive of the presence of at least two different sub-populations of WJ-MSC in our 333 
isolated cultures. 334 
Studies into the re-modelling of uterine spiral arteries have used cytokeratin-7 and karyotyping to conclude that 335 
placenta derived extra-villous trophoblast cells invade and modify these maternal vessels. However, in our study 336 
cytokeratin 7 (CK7) displayed a ubiquitous localisation in endothelial and human umbilical mesenchymal stem cells. 337 
The percentage of WJ-MSC showing positivity to CK 7 may be related to a specific cohort in the isolated stem cells 338 
or to a mesenchymal-epithelial transition of these cells in culture. However, this phenotype did not necessarily 339 
promote transmigration of stem cells; they were found in apical and basal locations at both 2 and 22h.  A recent 340 
study demonstrated the heterogeneity and intrinsic potential of WJ-MSC to express epithelial markers including CK 341 
7 in situ and in culture conditions [32]. Indeed, human bone marrow mesenchymal stem cells have been induced to 342 
express CK 7 [33], whilst a percentage of stem cells from the human amnion have also been shown to express CK 7 343 
in situ [34]. The endothelial localisation we found in HUVEC was curious; the co-expression of cytokeratin 7 and 344 
VE-cadherin (Fig 6) confirmed their endothelial phenotype but suggested a de-differentiation capability of fetal 345 
endothelial in conditions that favour proliferation and migration. The persistence of CK7 positive cells in the 346 
HUtMEC suggests this is not just a fetal trait. Moster et al. [35] suggested that anti-CK 7 alone is not adequate to 347 
distinguish between different trophoblast subtypes. Our studies further strengthen the concept that multiple markers 348 
need to be used when deciding trophoblast origin of fetal cells found in maternal spiral arteries. 349 
 Whilst fetal mesenchymal stem cells have been identified in maternal peripheral blood and damaged maternal 350 
tissues [9,10], how they cross the placental syncytiotrohoblast barrier into maternal intervillous blood lakes in the 351 
first instance remain unexplained. In the first trimester, mesenchymal stem cells invading the umbilical and villous 352 
cores may be able to migrate through cytotrophoblast cell shells or columns.  One could speculate that during 353 
gestation, chorionic villous regions, denuded of syncytiotrophoblast, may allow opportunistic escape of villous 354 
MSC. Furthermore, transient inflammatory/pressure events during pregnancy may cause breaches or induce 355 
transtrophoblastic channels in the syncytiotrophoblast; Kertschanska & Kaufmann presented morphological 356 
evidence of this in the 1990s and showed experimentally that they could be induced during fetal perfusion of human 357 
placental villi [36, 37]. Physiologically, villous MSC who are the nearest neighbours may be the ones that could 358 
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migrate during pregnancy, although this requires experimental demonstration and is beyond the remit of this paper. 359 
Regardless of anatomical location of isolated MSC from the extra-embryonic tissue, the ability of fetal MSC to 360 
interact with and influence uterine endothelial cells opens new avenues of enquiry regarding feto-maternal cross 361 
talk.  362 
In conclusion, the data obtained in this study addresses an important question as to how fetal stem cells cross the 363 
maternal endothelium. Moreover, the transit times for MSC transendothelial migration and the mechanisms 364 
employed may be valuable for stem cell cytotherapy.  Our data also opens a debate into how uterine spiral arteries 365 
are remodelled in pregnancy and whether other fetal stem cells, especially ones which can display non-destructive 366 
transendothelial migration and endothelial junctional repair may also be involved.  Finally, the perivascular support 367 
function shown by WJ-MSC both to fetal and adult endothelial cells increases the potential usefulness of these extra-368 
embryonic stem cells. 369 
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 477 
Figure legends 478 
Fig 1. Immunofluorescence analysis of HUtMEC grown in endothelial medium (A,B) and mixed media (C-F).  479 
(A). VE-cadherin show a predominant continuous staining pattern at cell-cell borders although some disruptions 480 
(arrow) are present; nuclei stained with PI. (B). HUtMEC also express CD31 at cell-cell boundaries; nuclei stained 481 
with DAPI. (C -F). VE-cadherin staining pattern in mixed media for 30 min, 2, 16 and 22h. Arrows point to 482 
discontinuous VE-Cadherin staining. (G) Graph showing % of continuous staining at different durations compared 483 
to control. Scale bar = 50 µm.   484 
 485 
Fig 2.  Spatio-temporal analyses of junctional VE-cadherin and WJ-MSC transmigration. 486 
A to F are co-culture images taken from coverslips inverted on microscope slides; Z focus on VE-cadherin (green) 487 
staining of HUtMEC. Bar = 50 µm.  (A) Apically resident PKH26 labelled WJ-MSC (red) showing rounded 488 
morphology and close association with overlying HUtMEC cell-cell boundaries at 30 minutes. (B)  Micrograph 489 
showing a rounded WJ-MSC overlying HUtMEC and a spindle-shaped WJ-MSC (arrow) under a disrupted junction 490 
at 2h.  (C, D) Increased number of cell-cell junctions with VE-Cadherin discontinuity or total loss of staining 491 
(arrows) can be seen in HUtMEC, 2 hours after addition of WJ-MSC.  (E) At 16h, more WJ-MSC (*) can now be 492 
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seen underlying HUtMEC. Arrow points to a WJ-MSC traversing the endothelial layer across a disrupted border. 493 
(F). At 22h, majority of junctions demonstrate continuous VE-Cadherin staining including those associated with 494 
basal WJ-MSC. (G). Z-tilt of VE-cadherin stained confocal images after 2h co-culture. WJ-MSC show paracellular, 495 
apical (a) and basal (b) location. (H). Z-tilt at 22h showing predominantly basal (sub-endothelial) location of WJ-496 
MSC. Bar = 100 µm. (I) Graph showing % of continuous VE-cadherin junctions at different duration of co-culture.  497 
Two-way ANOVA showed a decrease at 2 h (P < 0.0001) and increase at 22 h (P < 0.001). (J) Graph showing the 498 
increasing percentage of total WJ-MSC found in sub-endothelial position with time.  499 
 500 
Fig. 3. Time lapse images of WJ-MSC on HUtMEC monolayer.  501 
Micrographs showing sequential (every 15’) acquisitions with Z focus on the PKH26 labelled WJ-MSC (red) taken 502 
from 30 min after addition.  (A-M)  A rounded stem cell (*) can be seen displaying membrane blebbing as it moves 503 
on HUtMEC monolayer towards a paracellular cleft.  (N) The cell can be now be seen to change its rounded shape 504 
to a more spindle-shape morphology and has psuedopodial extensions. 2 other stem cells (1, 2) which could be seen 505 
out of plane of focus from Fig E are now in the same plane of focus in the cleft having moved to the same 506 
paracellular cleft.  (O) The starred cell  (*) now has a more elongated morphology and jostles for space in the 507 
paracellular cleft with the elongated spindle shaped cell 1 and intermediate shaped cell 2 (P,Q,R) . Bar = 14 µm.   508 
 509 
Fig. 4.  Immunoblot analyses of VE-cadherin, p-Tyr685 and p-Tyr731. 510 
(A) Immunoblots of HUtMEC co-cultured with (C0-C48h), without WJ-MSC (E0-E22h) and co-cultures in the 511 
presence of anti-VEGF (A2h & A22h). β-actin acted as loading control.  (B). Graph showing statistically significant 512 
increase in p-Tyr685/VE-cadherin at 0.5, 1, 2h and decrease at 22h and 48h (to normal basal level) in co-cultures.  513 
(C) Tyr731 shows a basal level of phosphorylation similar to the controls at 0, 0.5 and 1h, followed by a decrease in 514 
p-Tyr731 expression at 2h (p<0.001) and 22h (p<0.01). By 48h, phosphorylation status of p-Tyr is similar to normal. 515 
(D)  Graph showing VE-cadherin upregulation at 48h (p<0.01). (E) Graph showing effect of neutralising anti-VEGF 516 
on p-Tyr685 at 2 & 22h (p<0.01).  (F). Fluorescent micrograph of 22h co-culture grown in presence of anti-VEGF. 517 
Numerous WJ-MSC can be seen in both apical and basal (*) locations. Bar = 50 µm. 518 
 519 
Fig. 5. A. VEGF-A concentrations in conditioned media (CM) at different durations.  520 
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ELISA revealed negligible concentrations in WJ-MSC CM.  A detectable level was found in HUtMEC CM. 521 
HUtMEC grown in mixed media showed an increase at 2h which became undetectable at 22 and 48h. Addition of 522 
WJ-MSC resulted in increased VEGF-A at 2h (p < 0.001) followed by a decrease (p < 0.1) at 22h.  No VEGF-A was 523 
detected by 48h. VEGF-A was undetectable in co-cultures grown in the presence of VEGF-A neutralising 524 
antibodies. (Fig 5 B-D). Immunofluorescence images showing cytoplasmic localisation of VEGF-A (green) in 525 
HUTMEC and PKH26 (red) labelled WJ-MSC co-cultures. WJMSC show a higher intensity of staining at 2h (B); 526 
decreased intensity of staining was seen in both cell types by 48h (D). (E) Control image without primary antibody. 527 
No VEGF (green) staining can be seen in HUtMEC or  PKH26 (red) labelled WJ-MSC.  Bar = 50 µm. 528 
 529 
Fig 6. Cytokeratin-7 expression in endothelial and mesenchymal stem cells 530 
 (A) VE-cadherin (red) positive HUtMEC monolayer showing CK-7 intermediate filaments (green) in a proportion 531 
of cells. (B) A second source of HUtMEC showing the presence of VE-cadherin+ (now double labelled with FITC; 532 
green) and CK-7+ (red; TRITC) cells; nuclei – DAPI. (C & D) HUVEC cells showing dual positivity to VE-533 
cadherin (red) at cell-cell borders and CK-7 filaments (green).  (E) WJ-MSC monoculture showing 534 
immunonegativity to VE-cadherin (red) with a few cells demonstrating filamentous CK-7 green staining; nuclei- 535 
DAPI. (F) WJ-MSC monolayers immunolabelled with CK-7 (red) & the mesenchymal marker CD29 (green). A 536 
cohort of CD29+ cells show co-localisation with CK-7 (yellow). (G) PKH26 labelled WJ-MSC (w) on HUtMEC 537 
showing CK-7 expression (green) at 2h. (H) Sub-endothelial WJ-MSC (w) at 22h. Both CK-7 positive (green) and 538 
negative (red) cells can be seen. Bar = 50 µm. 539 
 540 
 541 
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Highlights 
• WJ-MSC show non-destructive paracellular transmigration across uterine endothelial cells 
• They alter VE-cadherin junctional occupancy to create frank paracellular gaps for extravasation 
• Mechanisms include VEGF-dependent phosphorylation  of Tyr685 and de-phosphorylation of Tyr731 
• Re-sealing of junctions and upregulation of VE-cadherin occurs once WJ-MSC are sub-endothelial 
